Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Citi
AstraZeneca
UBS
Deloitte
Boehringer Ingelheim
Covington
Cantor Fitzgerald
Merck

Generated: February 17, 2018

DrugPatentWatch Database Preview

ZIOPTAN Drug Profile

« Back to Dashboard

When do Zioptan patents expire, and what generic alternatives are available?

Zioptan is a drug marketed by Oak Pharms Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty patent family members in thirteen countries.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tafluprost profile page.
Summary for ZIOPTAN
Drug patent expirations by year for ZIOPTAN
Pharmacology for ZIOPTAN

US Patents and Regulatory Information for ZIOPTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ZIOPTAN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 0.0015% ➤ Subscribe 2/10/2016

Non-Orange Book US Patents for ZIOPTAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,985,920 Difluoroprostaglandin derivatives and their use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ZIOPTAN

Country Document Number Estimated Expiration
Canada 2225761 ➤ Sign Up
Norway 976085 ➤ Sign Up
Spain 2187719 ➤ Sign Up
European Patent Office 0850926 ➤ Sign Up
Germany 122008000050 ➤ Sign Up
Japan 2004002462 ➤ Sign Up
Japan 3480549 ➤ Sign Up
Norway 317060 ➤ Sign Up
Taiwan 536534 ➤ Sign Up
Netherlands 300407 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for ZIOPTAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
943 Luxembourg ➤ Sign Up 91943, EXPIRES: 20221222
C0020 France ➤ Sign Up PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
C013/2011 Ireland ➤ Sign Up SPC013/2011: 20110808, EXPIRES: 20221221
C/GB09/005 United Kingdom ➤ Sign Up PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017
9 Finland ➤ Sign Up
0850926/01 Switzerland ➤ Sign Up PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: SWISSMEDIC 60548 27.01.2010
0407 Netherlands ➤ Sign Up 300407, 20171222, EXPIRES: 20221221
2008 00041 Denmark ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Accenture
Healthtrust
Boehringer Ingelheim
McKesson
Deloitte
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot